Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Westerink, Lotte, Nicolai, Jelmer L. J., Samuelsen, Carl, Smit, Hans J. M., Postmus, Pieter E., Griebsch, Ingolf, Postma, Maarten J.
Published in The European journal of health economics (01.08.2020)
Published in The European journal of health economics (01.08.2020)
Get full text
Journal Article
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade
Westerink, Lotte, Wolters, Sharon, Zhou, Guiling, Postma, Arjan, Boersma, Cornelis, van Boven, Job Frank Martien, Postma, Maarten Jacobus
Published in The European journal of health economics (30.08.2024)
Published in The European journal of health economics (30.08.2024)
Get full text
Journal Article
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Westerink, Lotte, Nicolai, Jelmer Lennart Jens, Postma, Maarten Jacobus, van Boven, Job Frank Martien, Boersma, Cornelis
Published in PharmacoEconomics - open (01.09.2022)
Published in PharmacoEconomics - open (01.09.2022)
Get full text
Journal Article